Showing 1121-1130 of 1576 results for "".
- Bausch + Lomb Announces Topline Results From The First Phase 3 Trial Of NOV03 In Dry Eye Disease Associated With MGDhttps://modernod.com/news/bausch-lomb-announces-topline-results-from-the-first-phase-3-trial-of-nov03-in-dry-eye-disease-associated-with-mgd/2479072/Bausch + Lomb and Novaliq announced statistically significant topline data from the first phase 3 trial (GOBI trial) evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (D
- Zeiss Opens New High-Tech Center in San Francisco Bay Areahttps://modernod.com/news/zeiss-opens-new-high-tech-center-in-san-francisco-bay-area/2479038/Zeiss has completed construction of its new R&D, production, sales and customer service site in the San Francisco Bay Area. Bringing together hundreds of Zeiss employees and key functions under one roof, represents a major milestone in the company’s international innovation and growth
- Study: Drinking Wine May Help Protect Against Cataractshttps://modernod.com/news/study-drinking-wine-may-help-protect-against-cataracts/2479033/People who consume alcohol moderately appear less likely to develop cataracts that require surgery. Wine consumption showed the strongest protective effect, suggesting that antioxidants which are abundant in red wine may play a role in cataract prevention. However, people who d
- Kodiak Sciences Announces 1-Year Data from Ongoing Phase 1b Study of KSI-301 in Patients with Retinal Vascular Diseaseshttps://modernod.com/news/kodiak-sciences-announces-1-year-data-from-ongoing-phase-1b-study-of-ksi-301-in-patients-with-retinal-vascular-diseases/2478877/Kodiak Sciences announced promising 1-year durability, efficacy and safety data from the ongoing phase 1b study of its investigational therapy KSI-301, an intravitreal anti-VEGF antibody biopolymer conjugate, in patients with treatment-naïve wet age-related macular d
- Medicom Healthcare Signs Asset Purchase Agreement of Bimatoprost 0.3 mg/mL, 3mlhttps://modernod.com/news/medicom-healthcare-signs-asset-purchase-agreement-of-bimatoprost-0-3-mg-ml-3ml/2478852/Medicom Healthcare and Famar Health Care Services Madrid have announced the signing of an Asset Purchase Agreement (APA) for the acquisition by Medicom of the pharmaceutical dossier of Bimatorost 0.3 mg/mL, 3ml, preservative free eye drop solution, developed by Famar R&D. Under this agreement
- Neurophth Therapeutics Appoints Qiutang Li, PhD, as Chief Scientific Officerhttps://modernod.com/news/neurophth-therapeutics-appoints-qiutang-li-phd-as-chief-scientific-officer/2478800/Wuhan Neurophth Biotechnology, a developer of AAV-delivered gene therapies for the treatment of ocular diseases, announced the appointment of Qiutang Li, PhD, as Chief Scientific Officer. She will be mainly responsible for the company’s global R&D, IND portfolio strategy, and the establ
- Ace Vision Group Closes Series A Stock Round to Advance Ophthalmic Technologieshttps://modernod.com/news/ace-vision-group-closes-series-a-stock-round-to-advance-ophthalmic-technologies/2478790/Ace Vision Group announced that it closed a Series A preferred stock round totaling $13.3 million ($3.3 million oversubscribed) to continue development and commercialization of its VisioLite Ophthalmic Laser, a touchless therapeutic device being developed for the treatment of age-related vision d
- IRIS Registry Reveals Insights into Eye Disease Prevention and Treatmenthttps://modernod.com/news/worlds-largest-specialty-clinical-data-registry-reveals-insights-into-eye-disease-prevention-and-treatment/2478566/The IRIS Registry powered a number of big data studies this year, many of which were presented at AAO 2020 Virtual, the 124th annual meeting of the American Academy of Ophthalmology. The research findings are now available to view on demand. “With a growing pool of aggregated d
- Kodiak Sciences Announces Presentation of KSI-301 Phase 1b Clinical Study Data Focused on DME at AAO 2020 Virtual Meetinghttps://modernod.com/news/kodiak-sciences-announces-presentation-of-ksi-301-phase-1b-clinical-study-data-focused-on-dme-at-aao-2020-virtual-meeting/2478532/Kodiak Sciences announced that a pre-recorded presentation of clinical study data on its investigational therapy KSI-301 is available at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting. Details of the presentation are as follows: Event: Late Breaking D
- I-MED Pharma Launches Tearcheck Dry Eye Analysis in Canadahttps://modernod.com/news/i-med-pharma-launches-tearcheck-dry-eye-analysis-in-canada/2478522/I-MED Pharma announced the Canadian launch of tearcheck, a diagnostic and analyzing tool that performs 9 exams in under 10 minutes. The tearcheck was designed and developed by the French manufacturer E-Swin and offers the newest technological advancements to simplify dry eye d